[go: up one dir, main page]

RU95120403A - STIMULATOR OF ENDOGENOUS PRODUCTION OF CYTOKINES AND HEMOPOETHIC FACTORS AND METHOD OF ITS USE - Google Patents

STIMULATOR OF ENDOGENOUS PRODUCTION OF CYTOKINES AND HEMOPOETHIC FACTORS AND METHOD OF ITS USE

Info

Publication number
RU95120403A
RU95120403A RU95120403/14A RU95120403A RU95120403A RU 95120403 A RU95120403 A RU 95120403A RU 95120403/14 A RU95120403/14 A RU 95120403/14A RU 95120403 A RU95120403 A RU 95120403A RU 95120403 A RU95120403 A RU 95120403A
Authority
RU
Russia
Prior art keywords
glutathione
cytokines
oxidized
endogenous production
stimulator
Prior art date
Application number
RU95120403/14A
Other languages
Russian (ru)
Other versions
RU2089179C1 (en
Inventor
М.Б. Балазовский
Л.А. Кожемякин
Original Assignee
Закрытое акционерное общество "ВАМ"
Filing date
Publication date
Application filed by Закрытое акционерное общество "ВАМ" filed Critical Закрытое акционерное общество "ВАМ"
Priority claimed from RU95120403/14A external-priority patent/RU2089179C1/en
Priority to RU95120403/14A priority Critical patent/RU2089179C1/en
Priority to PCT/RU1996/000226 priority patent/WO1997021443A1/en
Priority to AU68391/96A priority patent/AU6839196A/en
Priority to US08/733,886 priority patent/US6165979A/en
Priority to APAP/P/1998/001260A priority patent/AP928A/en
Priority to RU98108088/14A priority patent/RU2153351C2/en
Priority to ES96941915T priority patent/ES2174124T3/en
Priority to JP09521965A priority patent/JP2000515111A/en
Priority to EP96941915A priority patent/EP0869809B1/en
Priority to PT96941915T priority patent/PT869809E/en
Priority to AU11130/97A priority patent/AU1113097A/en
Priority to DE69620233T priority patent/DE69620233T2/en
Priority to CN96199640.4A priority patent/CN1161149C/en
Priority to CA002239874A priority patent/CA2239874A1/en
Priority to PCT/RU1996/000340 priority patent/WO1997021444A1/en
Priority to DK96941915T priority patent/DK0869809T3/en
Priority to AT96941915T priority patent/ATE214936T1/en
Priority to US08/766,557 priority patent/US6251857B1/en
Publication of RU2089179C1 publication Critical patent/RU2089179C1/en
Application granted granted Critical
Publication of RU95120403A publication Critical patent/RU95120403A/en
Priority to OA9800083A priority patent/OA10698A/en
Priority to US09/702,701 priority patent/US6492329B1/en
Priority to US10/125,695 priority patent/US20030027770A1/en
Priority to JP2007238577A priority patent/JP2008001722A/en

Links

Claims (5)

1. Применение глутатиона окисленного, представляющего собой димер глутатиона восстановленного - трипептида со структурой γ-глутамилцистеинилглицина, в котором две молекулы трипептида с вышеозначенной структурой соединены друг с другом ковалентной дисульфидной связью между цистеиновыми остатками в качестве стимулятора эндогенной продукции цитокинов и гемопоэтических факторов.1. The use of oxidized glutathione, which is a reduced glutathione dimer — a tripeptide with a γ-glutamylcysteinylglycine structure, in which two tripeptide molecules with the above structure are joined together by a covalent disulfide bond between cysteine residues as a stimulator of endogenous production of cytokines and hematopoietic factors. 2. Средство для лечения онкологических, инфекционных, гематологических и других заболеваний, при которых целесообразна стимуляция эндогенной продукции цитокинов и гемопоэтических факторов, содержащее активное начало и фармацевтически приемлемый компонент, отличающееся тем, что в качестве активного начала содержит эффективное количество глутатиона окисленного. 2. An agent for the treatment of oncological, infectious, hematological and other diseases in which it is advisable to stimulate the endogenous production of cytokines and hematopoietic factors, containing an active principle and a pharmaceutically acceptable component, characterized in that it contains an effective amount of oxidized glutathione as an active principle. 3. Средство по п. 2, отличающееся тем, что представляет собой инъекционный раствор глутатиона окисленного в фармацевтически приемлемом растворителе в концентрации от 0,01 до 2,0%. 3. The tool according to p. 2, characterized in that it is an injection solution of glutathione oxidized in a pharmaceutically acceptable solvent in a concentration of from 0.01 to 2.0%. 4. Средство по п. 2, отличающееся тем, что для усиления и продления лечебного эффекта оно представляет собой инъекционный раствор глутатиона окисленного в перекиси водорода в концентрации 0,003%. 4. The tool according to p. 2, characterized in that to enhance and prolong the therapeutic effect, it is an injection of glutathione oxidized in hydrogen peroxide at a concentration of 0.003%. 5. Способ лечения онкологических, инфекционных, гематологических и других заболеваний, при которых целесообразна стимуляция эндогенной продукции цитокинов и гемопоэтических факторов, включающий введение парентерального средства по пп. 3 и 4 в дозах от 0,01 до 0,5 мг глутатиона окисленного на 1 кг массы тела, путем выполнения одной или более инъекций в день, курсами длительностью один или более дней или непрерывно до момента достижения лечебного эффекта. 5. A method of treating oncological, infectious, hematological and other diseases in which it is advisable to stimulate the endogenous production of cytokines and hematopoietic factors, including the introduction of a parenteral agent according to paragraphs. 3 and 4 in doses from 0.01 to 0.5 mg of glutathione oxidized per 1 kg of body weight, by performing one or more injections per day, in courses lasting one or more days or continuously until the therapeutic effect is achieved.
RU95120403/14A 1995-12-14 1995-12-14 Stimulator of cytokin and hemopoietic factors production and a method of its using RU2089179C1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (en) 1995-12-14 1995-12-14 Stimulator of cytokin and hemopoietic factors production and a method of its using
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
AU68391/96A AU6839196A (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US08/733,886 US6165979A (en) 1995-12-14 1996-10-18 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
APAP/P/1998/001260A AP928A (en) 1995-12-14 1996-12-01 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.
AU11130/97A AU1113097A (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
PCT/RU1996/000340 WO1997021444A1 (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
JP09521965A JP2000515111A (en) 1995-12-14 1996-12-10 Factors for enhancing endogenous production of cytokines and hematopoietic factors and methods of using the same
EP96941915A EP0869809B1 (en) 1995-12-14 1996-12-10 Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer
PT96941915T PT869809E (en) 1995-12-14 1996-12-10 OXIDIZED GLUTENTION FOR INCREASED CYTOCIN ENDOGENOUS PRODUCTION AND HEMATOPOIETIC FACTOR
RU98108088/14A RU2153351C2 (en) 1995-12-14 1996-12-10 Agent for regulation of endogenous production of cytokine and hemopoietic factor (variants) and method of its using
DE69620233T DE69620233T2 (en) 1995-12-14 1996-12-10 OXIDIZED GLUTATHION AS A MEANS TO IMPROVE THE ENDOGENIC PRODUCTION OF CYTOKINES AND HAEMATOPOIETIC FACTORS
CN96199640.4A CN1161149C (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and method of use thereof
CA002239874A CA2239874A1 (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
ES96941915T ES2174124T3 (en) 1995-12-14 1996-12-10 GLUTATION OXIDIZED AS AN INCREASER OF THE ENDOGENOUS PRODUCTION OF CYTOKINES AND HEMATOPOYETIC FACTORS.
DK96941915T DK0869809T3 (en) 1995-12-14 1996-12-10 Oxidized glutathione as an agent that increases endogenous cytokine production and hematopoietic factor
AT96941915T ATE214936T1 (en) 1995-12-14 1996-12-10 OXIDIZED GLUTATHIONE AS AN AGENT TO IMPROVE ENDOGENE PRODUCTION OF CYTOKINES AND HEMATOPOIETIC FACTORS
US08/766,557 US6251857B1 (en) 1995-12-14 1996-12-11 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
OA9800083A OA10698A (en) 1995-12-14 1998-06-12 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.
US09/702,701 US6492329B1 (en) 1995-12-14 2000-10-31 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US10/125,695 US20030027770A1 (en) 1995-12-14 2002-04-18 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
JP2007238577A JP2008001722A (en) 1995-12-14 2007-09-13 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (en) 1995-12-14 1995-12-14 Stimulator of cytokin and hemopoietic factors production and a method of its using

Publications (2)

Publication Number Publication Date
RU2089179C1 RU2089179C1 (en) 1997-09-10
RU95120403A true RU95120403A (en) 1998-02-10

Family

ID=20174317

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95120403/14A RU2089179C1 (en) 1995-12-14 1995-12-14 Stimulator of cytokin and hemopoietic factors production and a method of its using

Country Status (8)

Country Link
US (1) US6165979A (en)
CN (1) CN1161149C (en)
AU (1) AU6839196A (en)
DK (1) DK0869809T3 (en)
OA (1) OA10698A (en)
PT (1) PT869809E (en)
RU (1) RU2089179C1 (en)
WO (1) WO1997021443A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144374C1 (en) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Method of preparing of oxidized glutathione-cis- diaminodichloroplatinum complex and pharmaceutical compositions based on this complex for controlling metabolism, proliferation, and differentiation, and mechanisms of apoptosis of normal and transformated cells

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
DE69926994T2 (en) * 1998-01-19 2006-06-22 Takara Bio Inc., Otsu SUBSTANCES WHICH APOPTOSE CAN INTRODUCE
CA2320491A1 (en) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
JP4210454B2 (en) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
PT1328289E (en) * 2000-10-20 2008-12-10 Hamburger Stiftung Zur Foerder Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
DE10051983A1 (en) * 2000-10-20 2002-06-13 Beate Kehrel Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
NO20006008L (en) * 2000-11-28 2002-05-29 Thia Medica As Fatty acid analogues for the treatment of inflammatory and autoimmune diseases
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
RU2208443C2 (en) * 2001-02-20 2003-07-20 Самохин Григорий Георгиевич Method for treating multiple sclerosis
RU2202363C2 (en) * 2001-04-09 2003-04-20 Ершов Феликс Иванович Method for determining living organism and/or its cells sensitivity to acting field, substance or combinations of fields and/or substances
RU2183961C1 (en) * 2001-08-27 2002-06-27 Новицкий Юрий Алексеевич Hydrosulfate graphite-metallic complex and method to treat skin diseases (versions)
RU2208452C1 (en) * 2002-02-11 2003-07-20 Жуковский Юрий Георгиевич Method for increasing body resistance to higher pressure of respiratory gaseous medium
RU2218186C2 (en) * 2002-02-11 2003-12-10 Ростовский научно-исследовательский онкологический институт Method for treating the cases of non-operable cancer metastasizing into lymph nodes
RU2208453C1 (en) * 2002-02-11 2003-07-20 Жуковский Юрий Георгиевич Method for enhancement of body resistance against sea-sickness
RU2206334C1 (en) * 2002-02-11 2003-06-20 Жуковский Юрий Георгиевич Method of enhancement body resistance to heat effect
RU2206335C1 (en) * 2002-02-11 2003-06-20 Жуковский Юрий Георгиевич Method of enhancement of body resistance to hypothermic effect
RU2233663C2 (en) * 2002-07-09 2004-08-10 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Cytostatic factor of natural origin and method for its preparing
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
RU2311180C2 (en) * 2005-04-28 2007-11-27 Галина Викторовна Сукоян Agent for preventing progression of apoptotic and arresting necrotic alterations in body tissue
EA010926B1 (en) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Preparation for the treatment of ocular tuberculosis, method for preparation thereof and use
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
RU2451010C1 (en) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Palladium-copper catalysts for homogeneous selective oxidation of thiol groups, combination and composition based on said catalysts and therapeutic treatment method
EP2727932B1 (en) * 2011-06-30 2020-05-13 Kaneka Corporation Solid oxidized glutathione salt and method for producing same
RU2659161C1 (en) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Pharmaceutical composition comprising glutathione disulphide and glutathione disulfide s-oxide
CN114425051A (en) * 2022-03-07 2022-05-03 茂名市人民医院 Application of lipoic acid in preparation of medicine for treating sepsis and/or septic shock
CN114617899B (en) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 Application of S-adenosylmethionine in preparation of medicines for treating sepsis-related encephalopathy
CN121398829A (en) * 2023-04-03 2026-01-23 瓦列里·弗拉迪米罗维奇·图尔宾 Experimental methods for treating neoplastic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176983B (en) * 1984-10-16 1987-08-26 Zambon Spa DIPEPTIDES WITH PHARMACOLOGICAL ACTIVITY
US4927808A (en) * 1986-07-07 1990-05-22 Teijin Limited γ-L-glutamyl-L-cysteine ethyl ester and pharmaceutical compositions containing the same as an effective ingredient
ES2036553T3 (en) * 1986-10-07 1993-06-01 Boehringer Mannheim Italia S.P.A. PHARMACEUTICAL COMPOSITIONS THAT HAVE ANTINEOPLASTIC ACTIVITY.
US4968671A (en) * 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
JPH049336A (en) * 1990-04-26 1992-01-14 Yasuo Komoda Hypnotic agent
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
EP0502313B1 (en) * 1991-02-04 1997-07-16 Societe Des Produits Nestle S.A. Method for insuring adequate intracellular glutathione in tissue
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count
EP0831877B1 (en) * 1995-06-07 2004-10-27 Telik, Inc. Metabolic effects of certain glutathione analogs
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144374C1 (en) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Method of preparing of oxidized glutathione-cis- diaminodichloroplatinum complex and pharmaceutical compositions based on this complex for controlling metabolism, proliferation, and differentiation, and mechanisms of apoptosis of normal and transformated cells

Similar Documents

Publication Publication Date Title
RU95120403A (en) STIMULATOR OF ENDOGENOUS PRODUCTION OF CYTOKINES AND HEMOPOETHIC FACTORS AND METHOD OF ITS USE
EP0744409A4 (en) ACCELERATING THE SLATE GROWTH
DE69836352D1 (en) Transdermal therapeutic patch with capsaicin and its analogues
EA199800943A1 (en) UREA DERIVATIVES AND THEIR USE AS INHIBITORS INOSINE-5`-MONO-PHOSPHATE-DEHYDROGENASE INHIBITORS
EA200101005A1 (en) HIGHLY EFFICIENT COMPOSITIONS CONTAINING DIHYDROERGOTAMINE
MX9802734A (en) Novel stable liquid paracetamol compositions, and method for preparing same.
ATE395357T1 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ANEMIA
AR041770A1 (en) CYCLIC POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY AND PREPARATION PROCEDURE OF THE SAME
UY25374A1 (en) APOMORPHINE COMPOSITIONS USEFUL IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
ATE202931T1 (en) MEDICINAL PREPARATIONS CONTAINING TAXAN DERIVATIVES
IT1187828B (en) PHARMACEUTICAL COMPOSITION BASED ON DIPHOSPHONATES FOR THE TREATMENT OF ARETROSIS
KR880013977A (en) Anticoagulant Cyclic Peptides
DE69625682D1 (en) METHOD FOR TREATING IGNITIONS AND COMPOSITIONS THEREFOR
NO952336L (en) Insulin analogues
HUT52376A (en) Process for producing pharmaceutical compositions comprising 3-substituted-2-oxindole-1-carboxamide derivatives as active ingredient
EP1006793A4 (en) ANTI-ARRHYTHMIC COMPOSITIONS AND TREATMENT METHOD
ES2036560T3 (en) A METHOD FOR PREPARING A SYNERGICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF HYPERTENSION.
DE69110615D1 (en) Use of amino acids to protect ischemic heart tissue and its metabolic restoration.
EA200701017A1 (en) APPLICATION OF CYBOTINE RYBOSIS FOR THE TREATMENT OF HYPOXIA
AR036591A1 (en) USE OF HL IN CONTROLLED OVARIC HYPERESTIMULATION
RU2003113210A (en) TREATMENT OF CANCER DISEASES
KR890009974A (en) New compounds
EA200601579A1 (en) PEPTIDE, IMPROVING THE RESISTANCE OF CAPILLARIES, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD OF ITS APPLICATION
KR890700131A (en) New compounds
KR890000515A (en) An appetite suppressant cholestycomin analog